Pharmacokinetics of cisplatin in analbuminemic rats

被引:0
作者
Takada, K
Kawamura, T
Inai, M
Masuda, S
Oka, T
Yoshikawa, Y
Shibata, N [1 ]
Yoshikawa, H
Ike, O
Wada, H
Hitomi, S
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078414, Japan
[2] Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Drug Dosage Design, Sugitani, Toyama 93001, Japan
[3] Kyoto Univ Hosp, Dept Thorac Surg, Sakyou Ku, Kyoto 606, Japan
关键词
albumin; analbuminemic rat; cisplatin; pharmacokinetics; protein binding;
D O I
10.1002/1099-081X(199912)20:9<421::AID-BDD206>3.0.CO;2-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of protein binding on the pharmacokinetics of cisplatin (cis-diamminedichloro-platinum (II); CDDP) has been studied in analbuminemic rats, which genetically lack albumins, in comparison with normal rats. CDDP was reported to highly bind to serum components, and the major binder was thought: to be an albumin. However, there were no significant differences in the serum disappearance profiles of platinum after intravenous (iv) bolus injection of CDDP to analbuminemic rats as compared with normal rats. The total body clearance, Cl-tot, of platinum in normal rats was 48.7 +/- 22.0 mL h(-1) (5 mg kg(-1)), 55.9 +/- 4.04 mL h(-1) (10 mg kg(-1)) and 49.0 +/- 3.57 mL h(-1) (20 mg kg(-1)), whereas Cl-tot in analbuminemic rats was 52.0 +/- 8.48 mL h(-1) (5 mg kg(-1)), 62.9 +/- 10.8 mL h(-1) (10 mg kg(-1)) and 62.8 +/- 6.81 mL h(-1) (20 mg kg(-1)). The serum blood urea nitrogen (BUN) and creatinine levels at 6 h after iv injection were higher in both groups of rats who received CDDP than those of pre-dose level. However, there were no significant differences in the renal function tests between analbuminemic rats and normal rats. The binding of CDDP to the serum samples obtained from analbuminemic rats and normal rats was measured by a centrifuging filtration method. The binding percentages were 68.0 +/- 5.9% (2.0 mu g mL (-1)), 56.8 +/- 4.1% (5.0 mu g mL (-1)) and 64.6 +/- 4.4% (10.0 mu g mL (-1)) in analbuminemic rats and 52.9 +/- 3.5% (2.0 mu g mL (-1)), 52.2 +/- 3.4% (5.0 mu g mL (-1)), 56.9 +/- 1.9% (10.0 mu g mL (-1)) in normal rats. Higher binding percentages were obtained in analbuminemic rats than in normal rats. In vitro binding studies under the two incubation conditions (5 min and 2 h) showed that the binding percentages of CDDP to serum proteins were 59.2 +/- 3.2% (5 min) and 72.3 +/- 6.5% (2 h) for albumin, 42.3 +/- 1.9% (5 min) and 39.5 +/- 2.5% (2 h) for alpha(1)-acid glycoprotein (AAG) and 51.7 +/- 5.3% (5 min) and 49.2 +/- 1.9% (2 h) for gamma-globulin. From these studies, it was elucidated that albumin is not the major ligand in the rat serum and that other proteins also have important roles in the pharmacokinetics of CDDP. Copyright (C) 1999 John Wiley & Sons, Ltd.
引用
收藏
页码:421 / 428
页数:8
相关论文
共 30 条
[1]   Pharmacokinetics of cisplatin and its monohydrated complex in humans [J].
Andersson, A ;
Fagerberg, J ;
Lewensohn, R ;
Ehrsson, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (08) :824-827
[2]  
BEDNARSKI PJ, 1994, DRUG METAB DISPOS, V22, P419
[3]   THE ANTIMALARIAL DRUG HALOFANTRINE IS BOUND MAINLY TO LOW AND HIGH-DENSITY-LIPOPROTEINS IN HUMAN SERUM [J].
CENNI, B ;
MEYER, J ;
BRANDT, R ;
BETSCHART, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (05) :519-526
[4]   PREPARATION AND METABOLISM OF A CISPLATIN-SERUM PROTEIN COMPLEX [J].
COLE, WC ;
WOLF, W .
CHEMICO-BIOLOGICAL INTERACTIONS, 1980, 30 (02) :223-235
[5]  
COMIS RL, 1994, SEMIN ONCOL, V21, P109
[6]  
DECONTI RC, 1973, CANCER RES, V33, P1310
[7]  
Eastman A, 1996, PLATINUM AND OTHER METAL COORDINATION COMPOUNDS IN CANCER CHEMOTHERAPY 2, P283
[8]  
FORASTIERE AA, 1987, CANCER CHEMOTH PHARM, V19, P155
[9]  
GIBSON TP, 1980, APPLIED PHARMACOKINE, P32
[10]   PHARMACOKINETICS AND PROTEIN-BINDING OF CIS-DICHLORODIAMMINE PLATINUM (II) ADMINISTERED AS A ONE-HOUR OR AS A 20-HOUR INFUSION [J].
GULLO, JJ ;
LITTERST, CL ;
MAGUIRE, PJ ;
SIKIC, BI ;
HOTH, DF ;
WOOLLEY, PV .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1980, 5 (01) :21-26